Biovie (BIVI) Amortization - Intangibles (2016 - 2026)
Biovie (BIVI) posted Amortization - Intangibles of $57344.0 for Q1 2026, little changed sequentially from $57344.0 in Q4 2025, and little changed YoY from $57344.0 in Q1 2025.
Biovie (BIVI) Amortization - Intangibles (2016 - 2026) Analysis & Trends
Biovie has reported Amortization - Intangibles for 11 years, with the latest figure at $57344.0 in Q1 2026.
- Quarterly Amortization - Intangibles changed 0.0% year-over-year to $57344.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $229376.0 (changed 0.0% YoY) and the FY2025 annual result came in at $229377.0, changed 0.0% from the prior year.
- Amortization - Intangibles was little changed at $57344.0 in Q1 2026 per BIVI's latest filing, from $57344.0 in the prior quarter.
- Over five years, Amortization - Intangibles peaked at $57345.0 in Q2 2022 and troughed at $57344.0 in Q1 2022.
- A 5-year average of $57344.1 and a median of $57344.0 in 2022 frame the typical range for Amortization - Intangibles.
- The sharpest annual moves came in 2022 and 2023: Amortization - Intangibles changed 0.0% in 2022, then fell 0.0% in 2023.
- Over 5 years, Amortization - Intangibles stood at $57344.0 in 2022, then changed by 0.0% to $57344.0 in 2023, then changed by 0.0% to $57344.0 in 2024, then changed by 0.0% to $57344.0 in 2025, then changed by 0.0% to $57344.0 in 2026.
- According to Business Quant data, Amortization - Intangibles over the past three periods registered $57344.0, $57344.0, and $57344.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6,308.00 |
| Mar 31, 2026 | 57,344.00 |
| Dec 31, 2025 | 57,344.00 |
| Sep 30, 2025 | 57,344.00 |
| Jun 30, 2025 | 57,344.00 |
| Mar 31, 2025 | 57,344.00 |
| Dec 31, 2024 | 57,344.00 |
| Sep 30, 2024 | 57,344.00 |
| Jun 30, 2024 | 57,344.00 |
| Mar 31, 2024 | 57,344.00 |
| Dec 31, 2023 | 57,344.00 |
| Sep 30, 2023 | 57,344.00 |
| Jun 30, 2023 | 57,344.00 |
| Mar 31, 2023 | 57,344.00 |
| Dec 31, 2022 | 57,344.00 |
| Sep 30, 2022 | 57,344.00 |
| Jun 30, 2022 | 57,345.00 |
| Mar 31, 2022 | 57,344.00 |
| Dec 31, 2021 | 57,344.00 |
| Sep 30, 2021 | 57,344.00 |